# Ascenta Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ascenta-therapeutics

- Industry: Healthcare
- Headquarters: Malvern, US
- Website: www.ascenta.com
- Total disclosed funding: $86M
- Latest round: Series C (Apr 9, 2007)
- Investors on record: 7

## About

Ascenta Therapeutics, Inc. is a biotechnology firm focused on developing innovative therapeutic solutions to address unmet medical needs, leveraging advanced technology to enhance patient outcomes.Ascenta Therapeutics, Inc. specializes in biotechnology solutions that improve healthcare delivery. The company is headquartered in Malvern, US. Founded by Jianxin Duan, who has experience in founding other ventures, Ascenta has conducted four funding deals since its inception. The most recent deal occurred on February 19, 2010, when the company raised USD 1.8 mn in VENTURE DEBT, contributing to a total of USD 50.00 mn raised.The company specializes in delivering innovative therapeutic solutions that cater to healthcare industry needs, with a focus on advanced software applications and integrated service platforms. These solutions enhance operational efficiency and address critical challenges faced by healthcare providers, such as patient data management and treatment optimization. The primary customer base includes medium to large healthcare enterprises, utilizing these products to streamline processes and improve service delivery. Ascenta's products are deployed in key geographical markets including North America, Europe, and parts of Asia, offering reliable and effective solutions to operational challenges in healthcare.Ascenta Therapeutics generates revenue through a structured transaction model, primarily based on subscription services and direct sales of its software solutions. Clients engage with the firm through annual subscription agreements providing access to core offerings, including updates and customer support. The company also engages in B2B partnerships, integrating products into larger platforms serving the healthcare industry. Pricing plans are tailored based on deployment scale and service range, ensuring a steady income stream while fostering long-term relationships with key clients.Ascenta Therapeutics plans to develop and launch new therapeutic products aimed at enhancing treatment efficacy, with specific releases expected in the upcoming year. The company is also targeting expansion into new markets, specifically focusing on South America and Southeast Asia by late 2023. The recent funding of USD 1.8 mn from February 2010 will be utilized to support these initiatives, ensuring that their new product offerings and market expansion strategies are adequately financed.

## Funding rounds

- Series C, Apr 9, 2007, $50M — Domain Associates, Enterprise Partners Venture Capital, Sofinnova Investments, US Venture Partners, Perseus, Scale Venture Partners
- Series B, Mar 14, 2007, $30M — Domain Associates, Enterprise Partners Venture Capital, Sofinnova Investments, US Venture Partners, Bank of America Capital Investors
- Series A, Dec 5, 2003, $5.5M — Domain Associates, Enterprise Partners Venture Capital, Sofinnova Investments

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B, Series C
- Enterprise Partners Venture Capital (https://capitalatlas.ai/funds/enterprise-partners-venture-capital) — Series A, Series B, Series C
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B, Series C
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series B, Series C
- Bank of America Capital Investors (https://capitalatlas.ai/funds/bank-of-america-capital-investors) — Series B
- Perseus (https://capitalatlas.ai/funds/perseus) — Series C
- Scale Venture Partners (https://capitalatlas.ai/funds/scale-venture-partners) — Series C